Edition:
United Kingdom

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

1.11USD
6:12pm BST
Change (% chg)

$0.04 (+3.74%)
Prev Close
$1.07
Open
$1.06
Day's High
$1.13
Day's Low
$1.01
Volume
13,301
Avg. Vol
60,352
52-wk High
$17.92
52-wk Low
$0.94

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals Says Data Showed SNA-001 Met Primary Endpoint Of Non-Inferiority In Hair Reduction
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS’ NOVEL SILVER PHOTOPARTICLE TECHNOLOGY SNA-001 SUCCESSFULLY REMOVES LIGHT HAIR WHEN USED WITH COMMON LASER SYSTEM.SIENNA BIOPHARMACEUTICALS INC - SIENNA TO SEEK STRATEGIC PARTNER FOR SNA-001.SIENNA BIOPHARMACEUTICALS - WILL CONTINUE TO FOCUS ON PHASE 3 DEVELOPMENT OF SNA-120 FOR PSORIASIS AND PRURITUS AND ITS TOPICAL BY DESIGN PLATFORM.SIENNA BIOPHARMACEUTICALS INC - DATA SHOWED SNA-001 MET PRIMARY ENDPOINT OF NON-INFERIORITY IN HAIR REDUCTION.SIENNA BIOPHARMA - SNA-001 WAS STATISTICALLY SUPERIOR COMPARED TO VEHICLE+LASER, SHOWING UP TO A 31 PERCENT REDUCTION OF LIGHT HAIR FROM BASELINE.  Full Article

Sienna Biopharmaceuticals Reports Qtrly Loss Per Share $0.85
Monday, 14 May 2018 

May 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.85.  Full Article

Sienna Biopharmaceuticals Appoints John Smither As CFO
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER.SIENNA BIOPHARMACEUTICALS INC - ‍SMITHER WILL SUCCEED RICHARD PETERSON, WHO HAS RESIGNED FOR PERSONAL REASONS, EFFECTIVE MAR. 29, 2018​.  Full Article

Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56
Thursday, 15 Mar 2018 

March 15 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 TOTALED APPROXIMATELY $74.5 MILLION.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.56.  Full Article

Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125.SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM STUDY EXPECTED IN Q3 OF 2018.SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE DATA IN SECOND HALF OF 2018.SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA IN 1H 2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & ASSOCIATED UNDERLYING PSORIASIS.  Full Article

Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports third quarter 2017 financial results.Sienna Biopharmaceuticals Inc - Qtrly loss per share $1.12‍​.Sienna Biopharmaceuticals Inc - ‍Sienna's cash and cash equivalents as of Sept. 30, 2017, totaled approximately $88.6 million​.Sienna Biopharmaceuticals - ‍ Expects non-cash component related to acquisition of creabilis to continue to impact G&A expenses in future quarters​.  Full Article

Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120.Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​.Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​.  Full Article

Sienna Biopharmaceuticals reports Q2 loss of $6.50/shr
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports second quarter 2017 financial results.Qtrly loss per share $6.50.  Full Article

Partner Fund reports 7.7 pct passive stake in Sienna Biopharmaceuticals‍​
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Sienna Biopharmaceuticals Inc :Partner Fund Management LP reports 7.7 percent passive stake in Sienna Biopharmaceuticals Inc as of July 27, 2017 - SEC filing‍​.  Full Article

Sienna Biopharmaceuticals shares open 27 pct above IPO price in debut
Thursday, 27 Jul 2017 

July 27 (Reuters) - :Sienna Biopharmaceuticals Inc shares open at $19.05 in debut on the NASDAQ versus IPO price of $15.00.  Full Article